Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

被引：0
|
作者：
Cavo, Michele [1 ]
Bringhen, Sara [2 ]
Testoni, Nicoletta [1 ]
Omede, Paola [2 ]
Marzocchi, Giulia [1 ]
Ruggeri, Marina [2 ]
Durante, Sandra [1 ]
Di Raimondo, Francesco
Rossi, Davide
Gorgone, Ausilia
Patriarca, Francesca
Petrucci, Maria Teresa
Buttignol, Silvia
Levi, Anna
Offidani, Massimo
Nozzoli, Chiara
Ria, Roberto
Olivero, Barbara
Galli, Monica
Montefusco, Vittorio
Callea, Vincenzo
Falcone, Antonietta
De Vivo, Antonio [1 ]
Boccadoro, Mafio [2 ]
Terragna, Carolina [1 ]
Palumbo, Antonio [2 ]
机构：
[1] Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy
[2] Univ Turin, Div Hematol, Turin, Italy
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：741 / 741
页数：1
相关论文
共 50 条
  • [1] IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS
    Cavo, M.
    Palumbo, A.
    Bringhen, S.
    Di Raimondo, F.
    Patriarca, F.
    Rossi, D.
    Levi, A.
    Offidani, M.
    Montefusco, V.
    Narni, F.
    Zambello, R.
    Benevolo, G.
    Grasso, M.
    Falcone, A.
    Musto, P.
    Guglielmelli, T.
    Gherlinzoni, F.
    Gottardi, D.
    Musolino, C.
    Di Renzo, N.
    Masini, L.
    Cangialosi, C.
    Dore, F.
    Ballanti, S.
    Storti, S.
    Angelucci, E.
    Vallone, R.
    Magarotto, V.
    Morabito, F.
    Tosi, P.
    Boccadoro, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 451 - 451
  • [2] The Choice Of Regimens Based On Bortezomib For Patients With Newly Diagnosed Multiple Myeloma
    Yang, Li
    He, Jingsong
    Han, Xiaoyan
    Zheng, Gaofeng
    Zheng, Weiyan
    Wei, Guoqing
    Wu, Wenjun
    Ye, Xiujin
    Shi, Jimin
    Xie, Wanzhuo
    Li, Li
    Zhang, Jie
    Huang, Weijia
    Zhao, Yi
    Huang, He
    Zhang, Xuejin
    Fu, Jiaping
    Cai, Zhen
    [J]. BLOOD, 2013, 122 (21)
  • [3] The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
    He, Jingsong
    Yang, Li
    Han, Xiaoyan
    Zheng, Gaofeng
    Zheng, Weiyan
    Wei, Guoqing
    Wu, Wenjun
    Ye, Xiujin
    Shi, Jimin
    Xie, Wanzhuo
    Li, Li
    Zhang, Jie
    Huang, Weijia
    Zhao, Yi
    Huang, He
    Zhang, Xuejin
    Fu, Jiaping
    Cai, Zhen
    [J]. PLOS ONE, 2014, 9 (06):
  • [4] Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
    Zhou, Qiaolin
    Xu, Fang
    Wen, Jingjing
    Yue, Jing
    Zhang, Ya
    Su, Jing
    Liu, Yiping
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (05) : 1573 - 1580
  • [5] Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
    Cavo, Michele
    Bringhen, Sara
    Terragna, Carolina
    Omede, Paola
    Marzocchi, Giulia
    Ruggeri, Marina
    Durante, Sandra
    Petrucci, Maria Teresa
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Montefusco, Vittorio
    Narni, Franco
    Falcone, Antonietta
    Califano, Catello
    Baraldi, Anna
    Pasini, Silvana
    Galieni, Piero
    Morabito, Fortunato
    Grasso, Mariella
    Gottardi, Daniela
    Rizzo, Vincenzo
    Boccadoro, Mario
    Testoni, Nicoletta
    Palumbo, Antonio
    [J]. BLOOD, 2010, 116 (21) : 342 - 343
  • [6] Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
    Qiaolin Zhou
    Fang Xu
    Jingjing Wen
    Jing Yue
    Ya Zhang
    Jing Su
    Yiping Liu
    [J]. Clinical and Experimental Medicine, 2023, 23 : 1573 - 1580
  • [7] CMV REACTIVATION IN MULTIPLE MYELOMA TREATED WITH BORTEZOMIB-BASED REGIMENS
    Sampath, V. S.
    Yee, A. Tso Ching
    Lee, L. K.
    Fong, S. Z.
    Lim, Y. C.
    Ponnudurai, K.
    Rajendran, J.
    Ong, K. H.
    [J]. HAEMATOLOGICA, 2014, 99 : 752 - 752
  • [8] Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
    Liu, Xiao
    Jia, Shuangshuang
    Chu, Yuping
    Tian, Biao
    Gao, Yaya
    Zhang, Chunyan
    Zheng, Yanhua
    Jia, Weijing
    Liu, Xiangxiang
    Yuan, Ruifeng
    Zhang, Na
    Feng, Juan
    Dong, Hongjuan
    Xin, Xiaoli
    Cao, Zhengcong
    Tang, Hailong
    Chang, Ziwei
    Gao, Guangxun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Treatment of newly diagnosed myeloma: Bortezomib-based triplet
    Rajan, Archana M.
    Rajkumar, S. Vincent
    [J]. SEMINARS IN ONCOLOGY, 2016, 43 (06) : 700 - 702
  • [10] Renal dysfunction does not affect clinical response in multiple myeloma (MM) patients treated with bortezomib-based regimens
    Ailawadhi, Sikander
    Mashtare, Terry L.
    Coignet, Marie V.
    Depaolo, Dawn M.
    Miller, Kena C.
    Wilding, Gregory
    Chanan-Khan, Asher Alban
    [J]. BLOOD, 2007, 110 (11) : 442A - 442A
12345